BCL2L1 and hematologic disorder: Since BCL-XL is widely overexpressed and an essential gene in multiple solid tumors (Figs. 3 and 4), compounds that selectively target BCL-XL may have the potential to translate promising results from hematological malignancies into the field of solid tumors dependent on BCL-XL for survival.